Evaluate Therapeutic Drugs that Target SARS-CoV-2 Replication
The 3CLglow Assay is a SARS-CoV-2 3CLpro inhibitor assay, a new technology developed by Montana Molecular in response to the COVID-19 pandemic. This assay provides a robust, biologically meaningful tool to evaluate therapeutic drugs that target SARS-CoV-2 replication.
- 3C-like protease (3CLpro, Mpro, or Main protease) is essential for SARS-CoV-2 replication
- Discover new 3CL protease inhibitors
- A single BacMam delivers a gene encoding the green fluorescent 3CLglow Sensor as well as constitutively expressed red protein to check cell health
- BSL-1 kit is safe and easy to use
Simple Assay Steps
- Day 1 - Plate 35,000 HEK293 cells in each well
- Day 2 - Make transduction mix by combining 3CLglow BacMam, 3CLpro Enzyme, complete media, and sodium butyrate (included in 3CLglow Assay Kit)
- Day 3 - Add inhibitor compounds and measure green and red fluorescence in either an endpoint assay to maximize throughput, or a kinetic assay for real-time detection of inhibitor action in living cells
Read More
Download Protocol
Order 3CLglow Assay Kit
Related Products:
COVID-19 Drug Screening / Pseudovirus Neutralization Assay
- Fluorescent SARS-CoV-2 cell entry assay based on two components: The first is a BacMam expression vector coding for human ACE2 to transform any cell into pseudo host cells. The second assay component is a SARS-CoV-2 Pseudovirus - a modified BacMam presenting the Spike protein on the surface of the BacMam capsid
- Identify therapeutic drugs that block Spike ACE2 binding
- No BSL-3 safety requirements
- Screen for neutralizing antibodies to SARS-CoV-2 spike and emerging spike variants
- BacMam is high-titer and more cost-effective to use than Lentivirus-based assays